Author/Authors :
Chen، نويسنده , , Xuesong and Meng، نويسنده , , Qingwei and Zhao، نويسنده , , Yanbin and Liu، نويسنده , , Meiyan and Li، نويسنده , , Dandan and Yang، نويسنده , , Yanmei and Sun، نويسنده , , Lichun and Sui، نويسنده , , Guangjie and Cai، نويسنده , , Li and Dong، نويسنده , , Xiaoqun، نويسنده ,
Abstract :
Angiotensin II type 1 receptor (AT1R) promotes tumor invasion, migration, metastasis and angiogenesis. We explored the potential antitumor effects of AT1R antagonists in breast cancer. We found that angiotensin II promoted cell proliferation and upregulated the expression of vascular endothelial growth factor A (VEGF-A) in MCF-7 cells. Losartan downregulated the expression of VEGF-A in MCF-7 cells treated with angiotensin II. Candesartan downregulated the expression of VEGF-A in mice bearing MCF-7 xenografts and inhibited tumor growth and angiogenesis. AT1R and VEGF-A expression correlated with increased microvascular density in 102 breast cancer patients. Our data suggest that AT1R antagonists might be useful to suppress breast cancer by inhibiting the angiotensin II.
Keywords :
breast cancer , Vascular endothelial growth factor (VEGF) A , Angiotensin II type 1 receptor (AT1R) , Angiotensin (AT) II
